Affinium Pharmaceuticals
Edit Page
Report
Scan day: 12 February 2014 UTC
10
Virus safety - good
Description: Developer of a novel class of antibiotics, under license to major manufacturers. Including marketing profile, news archive and contacts in Toronto, Canada.
Debiopharm has purchased Affinium’s platform and clinical assets and will continue to develop new antibiotics for patients worldwide Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company, and Affinium Pharmaceuticals (Affinium), announced as of February 11th, 2014, the acquisition by Debiopharm of Affinium’s clinical and preclinical assets as well as its technology platform.
Size: 408 chars
Contact Information
Email: —
Phone&Fax: —
Address: —
Extended: —
WEBSITE Info
| Page title: | Affinium Pharmaceuticals |
| Keywords: | |
| Description: | |
| IP-address: | 209.245.121.191 |
WHOIS Info
| NS | Name Server: AUTH01.DNS.ACCELERATEDCONNECTIONS.COM Name Server: AUTH02.DNS.ACCELERATEDCONNECTIONS.COM |
| WHOIS | Status: clientTransferProhibited |
| Date | Creation Date: 25-oct-2001 Expiration Date: 25-oct-2018 |